Key facts
- The Trump administration finalized a rule to end federal support for gender-affirming care.
- The rule impacts individuals covered by Medicaid and CHIP.
- The policy takes effect on October 13.
- Opponents criticize the move as politically motivated.
- Opponents state the rule is harmful to vulnerable children.
- The administration cites a lack of evidence for safety and clinical benefit.
- Federal support for gender-affirming care will be ended through Medicaid and CHIP.
The Trump administration has finalized a rule that will terminate federal support for gender-affirming care. This policy specifically impacts individuals enrolled in Medicaid and the Children’s Health Insurance Program (CHIP). The rule is set to become effective on October 13. Critics of the administration's decision argue that the move is politically motivated and will inflict harm upon vulnerable children. They contend that access to gender-affirming care is crucial for the well-being of these young individuals. Conversely, the administration has put forth a justification for the finalized rule, citing a perceived absence of sufficient evidence to support the safety and clinical efficacy of gender-affirming treatments. This rationale forms the basis of their policy change, aiming to redirect federal funds away from these services.